---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-334588"
form_type: "8-K"
ticker: "NGNE"
cik: "0001404644"
company_name: "Neurogene Inc."
filed_at: "2021-11-19T23:59:59+00:00"
generated_at: "2026-06-28T06:28:45.840137+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Neoleukin Therapeutics General Counsel Holly Vance resigns

## Summary
- Holly Vance resigns as General Counsel and Corporate Secretary effective Nov 17, 2021 to pursue another opportunity.
- Transition period under negotiation; Vance expected to provide consulting services as needed.
- No replacement named; CFO Robert Ho signs the filing.

## SEC filing metadata
- accession: 0001193125-21-334588
- form_type: 8-K
- ticker: NGNE
- cik: 0001404644
- company_name: Neurogene Inc.
- filed_at: 2021-11-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404644/000119312521334588/0001193125-21-334588-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404644/000119312521334588/d259869d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-334588
- JSON: https://secwatch.observer/filing/0001193125-21-334588.json
- Plain text: https://secwatch.observer/filing/0001193125-21-334588.txt

## Key facts
- Executive change
  Holly Vance resigned as General Counsel and Corporate Secretary at Neurogene Inc..
  - Action: resigned
  - Role: General Counsel and Corporate Secretary
  source text: On November 17, 2021, Neoleukin Therapeutics, Inc. (the “Company”) received notice from Holly Vance of her intention to resign as the Company’s General Counsel and Corporate Secretary to pursue another opportunity.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1404644/000119312521334588/0001193125-21-334588-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.